Ambika G. Bajpayee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ambika G. Bajpayee has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
Armin Vedadghavami
Department of Bioengineering, Northeastern University, 360 Huntington Avenue, Boston, Massachusetts 02115, United States
8 shared publicationsTengfei He
Department of Bioengineering, Northeastern University, 360 Huntington Avenue, Boston, Massachusetts 02115, United States
7 shared publicationsChenzhen Zhang
Department of Bioengineering, Northeastern University, Boston, MA, USA
6 shared publications- Bill Hakim
Department of Bioengineering, Northeastern University
5 shared publications - Chenzhen Zhang
Department of Bioengineering, Northeastern University, Boston, MA 02115, USA
5 shared publications Helna M. Baby
Department of Bioengineering, Northeastern University, Boston, USA
5 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Springer Nature in Arthritis Research & Therapy
Advancing IL-1 inhibition for OA: Lessons learned from clinical trials and new approaches
- 8 October 2026
- Published by Springer Nature in Arthritis Research & Therapy
Open AccessAdvancing IL-1 inhibition for OA: Lessons learned from clinical trials and new approaches
- Open Access
- 9 May 2026
- Published by Elsevier in Acta Biomaterialia
- Vol. 217, 665-679
Charge-engineered microparticles for targeted delivery of RhoA activator to nucleus pulposus
- 9 May 2026
- Published by Elsevier in Acta Biomaterialia
- Vol. 217, 665-679
Open AccessCharge-engineered microparticles for targeted delivery of RhoA activator to nucleus pulposus
- Top Cited PapersOpen Access
- 9 April 2026
- Published by Springer Nature in npj Biomedical Innovations
- Vol. 3 (1)
Peptide-based targeted drug delivery strategies for osteoarthritis treatment
Peptide-based strategies offer promising solutions to overcome the complex, multi-tissue barriers of osteoarthritis. Their tunability, specificity, and versatility enable targeted drug delivery to cartilage, synovium, and subchondral bone, while some therapeutic peptides provide intrinsic anti-inflammatory, regenerative, or analgesic effects. Advances in peptide design, stability engineering, and in silico screening, alongside emerging human joint-on-chip models, are accelerating the development of targeted, stable, multi-tissue OA therapies.
- 9 April 2026
- Published by Springer Nature in npj Biomedical Innovations
- Vol. 3 (1)
Top Cited PapersOpen AccessPeptide-based targeted drug delivery strategies for osteoarthritis treatment
Peptide-based strategies offer promising solutions to overcome the complex, multi-tissue barriers of osteoarthritis. Their tunability, specificity, and versatility enable targeted drug delivery to cartilage, synovium, and subchondral bone, while some therapeutic peptides provide intrinsic anti-inflammatory, regenerative, or analgesic effects. Advances in peptide design, stability engineering, and in silico screening, alongside emerging human joint-on-chip models, are accelerating the development of targeted, stable, multi-tissue OA therapies.
- 24 December 2025
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 34 (4) , 563-574
Engineered cationic Interleukin-1 receptor antagonist outperforms anakinra at joint retention and preventing IL-1-induced cartilage inflammation
- 24 December 2025
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 34 (4) , 563-574
Engineered cationic Interleukin-1 receptor antagonist outperforms anakinra at joint retention and preventing IL-1-induced cartilage inflammation
- Open Access
- 13 November 2025
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 17 (44) , 25664-25679
Extended osteoarthritis pain relief with neosaxitoxin using alginate-core polymeric microparticles
We developed a sustained release alginate-core polymeric microparticle formulation (NSTX-AlgPLGA-MP) to extend the analgesic effect of Neosaxitoxin (NSTX) for osteoarthritis (OA) pain from hours to approximately one week.
- 13 November 2025
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 17 (44) , 25664-25679
Open AccessExtended osteoarthritis pain relief with neosaxitoxin using alginate-core polymeric microparticles
We developed a sustained release alginate-core polymeric microparticle formulation (NSTX-AlgPLGA-MP) to extend the analgesic effect of Neosaxitoxin (NSTX) for osteoarthritis (OA) pain from hours to approximately one week.
- 18 September 2025
- Published by Elsevier in Biophysical Journal
- Vol. 124 (21) , 3690-3705
Spatial charge-hydrophobicity configuration modulates cationic peptide transport in cartilage
- 18 September 2025
- Published by Elsevier in Biophysical Journal
- Vol. 124 (21) , 3690-3705
Spatial charge-hydrophobicity configuration modulates cationic peptide transport in cartilage
- 11 April 2025
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 33 (6) , 721-734
Cartilage targeting cationic peptide carriers display deep cartilage penetration and retention in a rabbit model of post-traumatic osteoarthritis
- 11 April 2025
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 33 (6) , 721-734
Cartilage targeting cationic peptide carriers display deep cartilage penetration and retention in a rabbit model of post-traumatic osteoarthritis
- Top Cited PapersOpen Access
- 31 March 2025
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 33 (7) , 835-847
Cartilage-targeting exosomes for delivery of receptor antagonist of interleukin-1 in osteoarthritis treatment
- 31 March 2025
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 33 (7) , 835-847
Top Cited PapersOpen AccessCartilage-targeting exosomes for delivery of receptor antagonist of interleukin-1 in osteoarthritis treatment
- Open Access
- 18 September 2024
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 16 (41) , 19174-19191
Harnessing exosomes for advanced osteoarthritis therapy
Exosomes show promise as next-generation therapy for osteoarthritis (OA) due to their ability to modulate inflammation and cartilage synthesis. Recent advances in the engineering of exosomes have enhanced their targeted therapeutic potential for OA.
- 18 September 2024
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 16 (41) , 19174-19191
Open AccessHarnessing exosomes for advanced osteoarthritis therapy
Exosomes show promise as next-generation therapy for osteoarthritis (OA) due to their ability to modulate inflammation and cartilage synthesis. Recent advances in the engineering of exosomes have enhanced their targeted therapeutic potential for OA.
- Open Access
- 8 August 2024
- Published by Elsevier in Journal of Biomechanics
- Vol. 174, 112265
Effect of dynamic loading on calcium signaling in In-Situ chondrocytes
- 8 August 2024
- Published by Elsevier in Journal of Biomechanics
- Vol. 174, 112265
Open AccessEffect of dynamic loading on calcium signaling in In-Situ chondrocytes